Figure 4
Radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin). Pretreatment (A) and posttreatment (B) CT imaging of a patient with OAML involving the right orbit (arrow), demonstrating a complete response 12 weeks after radioimmunotherapy.
Radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin). Pretreatment (A) and posttreatment (B) CT imaging of a patient with OAML involving the right orbit (arrow), demonstrating a complete response 12 weeks after radioimmunotherapy.
